BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38340443)

  • 61. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 62. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
    Fagan V; Bonham S; Carty MP; Saenz-Méndez P; Eriksson LA; Aldabbagh F
    Bioorg Med Chem; 2012 May; 20(10):3223-32. PubMed ID: 22522008
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antioxidative enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) modulates the differentiation of Th17 cells by regulating ROS levels.
    Nishida-Tamehiro K; Kimura A; Tsubata T; Takahashi S; Suzuki H
    PLoS One; 2022; 17(7):e0272090. PubMed ID: 35905076
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduction of nitroaromatic compounds by NAD(P)H:quinone oxidoreductase (NQO1): the role of electron-accepting potency and structural parameters in the substrate specificity.
    Miseviciene L; Anusevicius Z; Sarlauskas J; Cenas N
    Acta Biochim Pol; 2006; 53(3):569-76. PubMed ID: 16929382
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis, Characterization, and Biomedical Applications of a Targeted Dual-Modal Near-Infrared-II Fluorescence and Photoacoustic Imaging Nanoprobe.
    Cheng K; Chen H; Jenkins CH; Zhang G; Zhao W; Zhang Z; Han F; Fung J; Yang M; Jiang Y; Xing L; Cheng Z
    ACS Nano; 2017 Dec; 11(12):12276-12291. PubMed ID: 29202225
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
    Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA
    Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816
    [TBL] [Abstract][Full Text] [Related]  

  • 67. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
    Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
    Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
    Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
    Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis.
    Mandal RK; Dubey S; Panda AK; Mittal RD
    Tumour Biol; 2014 Jul; 35(7):6415-23. PubMed ID: 24676794
    [TBL] [Abstract][Full Text] [Related]  

  • 70. NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype.
    Lee J; Kim KS; Lee MH; Kim YS; Lee MH; Lee SE; Kim YK; Ryu MJ; Kim SJ; Choi MJ; Jo YS
    Yonsei Med J; 2013 Sep; 54(5):1158-67. PubMed ID: 23918565
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Human NAD(P)H:quinone oxidoreductase inhibition by flavonoids in living cells.
    Lee YY; Westphal AH; de Haan LH; Aarts JM; Rietjens IM; van Berkel WJ
    Free Radic Biol Med; 2005 Jul; 39(2):257-65. PubMed ID: 15964517
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
    Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
    Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
    Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
    J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Near-Infrared Fluorogenic Probes with Polarity-Sensitive Emission for in Vivo Imaging of an Ovarian Cancer Biomarker.
    Yao D; Lin Z; Wu J
    ACS Appl Mater Interfaces; 2016 Mar; 8(9):5847-56. PubMed ID: 26910257
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer.
    Cui X; Jin T; Wang X; Jin G; Li Z; Lin L
    Oncol Rep; 2014 Dec; 32(6):2589-95. PubMed ID: 25231218
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
    Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
    Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
    Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combined molecular modelling and 3D-QSAR study for understanding the inhibition of NQO1 by heterocyclic quinone derivatives.
    López-Lira C; Alzate-Morales JH; Paulino M; Mella-Raipán J; Salas CO; Tapia RA; Soto-Delgado J
    Chem Biol Drug Des; 2018 Jan; 91(1):29-38. PubMed ID: 28643389
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
    Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.